Real-World Study Assesses Lecanemab Eligibility in French Alzheimer's Patients
Eligibility for lecanemab treatment in a French memory clinic setting.
Background
Alzheimer's disease is a progressive neurodegenerative disorder characterized by cognitive decline, with amyloid-beta plaque accumulation being a hallmark. Lecanemab is a recently approved monoclonal antibody designed to clear these amyloid-beta plaques, offering a new therapeutic avenue for early-stage Alzheimer's disease. However, the proportion of patients in routine clinical practice who meet the strict eligibility criteria for lecanemab treatment remains unclear, posing a significant challenge for real-world implementation.